AARD insider transaction filings
Aardvark Therapeutics, Inc. — 30 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-11. Screen AARD transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 5 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 1 filing by 1 insider — 76,754 shares, $394,957 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 4.
- Largest priced transaction: sale of 62,000 shares @ $5.18 ($321,179) by Sun Nelson, filed 2026-09-11.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Sun Nelson — See Remarks | 1 | — | 2 legs · 76,754 sh · $394,957 | — |
| Baynes Roy D. — Director | 1 | — | — | 1 |
| Chi Jeffrey — Director | 1 | — | — | 1 |
| Graf Susan E — Director | 1 | — | — | 1 |
| Tong Victor Edward Jr — Director | 1 | — | — | 1 |
Recent Form 4 filings — Aardvark Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-11 | 4 | Sun Nelson — See Remarks | Sale (S): 14,754 @ $5.00 · Sale (S): 62,000 @ $5.18 | EDGAR |
| 2026-08-21 | 4 | Chi Jeffrey — Director | Grant/award (A): 44,964 (derivative) @ $0 | EDGAR |
| 2026-08-21 | 4 | Tong Victor Edward Jr — Director | Grant/award (A): 44,964 (derivative) @ $0 | EDGAR |
| 2026-08-21 | 4 | Baynes Roy D. — Director | Grant/award (A): 44,964 (derivative) @ $0 | EDGAR |
| 2026-08-21 | 4 | Graf Susan E — Director | Grant/award (A): 44,964 (derivative) @ $0 | EDGAR |
| 2026-02-11 | 4 | Sun Nelson — Chief Financial Officer | Grant/award (A): 70,549 (derivative) @ $0 | EDGAR |
| 2026-02-11 | 4 | Lee Tien-Li — Chief Executive Officer, Director, 10% owner | Grant/award (A): 203,851 (derivative) @ $0 | EDGAR |
| 2026-02-11 | 4 | Jaiman Manasi — Chief Medical Officer | Grant/award (A): 70,549 (derivative) @ $0 | EDGAR |
| 2025-12-12 | 4 | Sun Nelson — Chief Financial Officer | Purchase (P): 3,000 @ $14.40 | EDGAR |
| 2025-12-12 | 4 | Lee Tien-Li — Chief Executive Officer, Director, 10% owner | Purchase (P): 7,000 @ $14.48 | EDGAR |
| 2025-10-16 | 4 | Lee Tien-Li — Chief Executive Officer, Director, 10% owner | Option exercise (M): 1,229 @ $4.24 · Option exercise (M): 1,229 (derivative) @ $0 | EDGAR |
| 2025-10-16 | 4 | Jones Bryan — Chief Operating Officer | Option exercise (M): 1,250 @ $4.24 · Option exercise (M): 1,250 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | Lee Tien-Li — Chief Executive Officer, Director, 10% owner | Purchase (P): 6,500 @ $9.51 · Purchase (P): 3,500 @ $9.94 | EDGAR |
| 2025-09-12 | 4 | Lee Tien-Li — Chief Executive Officer, Director, 10% owner | Purchase (P): 9,000 @ $7.91 · Purchase (P): 6,000 @ $7.82 · Purchase (P): 5,000 @ $8.50 | EDGAR |
| 2025-09-10 | 4 | Sun Nelson — Chief Financial Officer | Purchase (P): 6,000 @ $8.07 | EDGAR |
| 2025-08-29 | 4 | Lee Tien-Li — Chief Executive Officer, Director, 10% owner | Option exercise (M): 17,209 @ $4.24 · Option exercise (M): 17,209 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Lee Tien-Li — Chief Executive Officer, Director, 10% owner | Grant/award (A): 549,534 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Chi Jeffrey — Director | Grant/award (A): 61,017 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Jaiman Manasi — Chief Medical Officer | Grant/award (A): 126,999 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Sun Nelson — Chief Financial Officer | Grant/award (A): 209,826 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Tong Victor Edward Jr — Director | Grant/award (A): 61,017 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Jones Bryan — Chief Operating Officer | Grant/award (A): 122,033 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Baynes Roy D. — Director | Grant/award (A): 30,508 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Graf Susan E — Director | Grant/award (A): 30,508 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Chi Jeffrey — Director | Conversion (C): 133,364 · Conversion (C): 1,130,135 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Vickers Venture Fund VI Pte Ltd — 10% owner | Conversion (C): 1,637,411 · Conversion (C): 413,491 · Conversion (C): 13,875,429 (derivative) @ $0 · Conversion (C): 3,503,919 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Lee Tien-Li — Chief Executive Officer, Director, 10% owner | Conversion (C): 41,303 · Purchase (P): 16,542 @ $16 · Conversion (C): 350,002 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Sun Nelson — Chief Financial Officer | Conversion (C): 7,001 · Purchase (P): 10,000 @ $16 · Conversion (C): 59,332 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Cormorant Asset Management, LP Chen Bihua | Conversion (C): 800,189 · Purchase (P): 187,500 @ $16 · Conversion (C): 6,780,810 (derivative) | EDGAR |
| 2025-02-19 | 4 | Decheng Capital Global Life Sciences Fund IV, L.P. — 10% owner Decheng Capital Management IV (Cayman), LLC — 10% owner Decheng Capital Global Healthcare Fund (Master), LP — 10% owner Decheng Capital Global Healthcare GP, LLC — 10% owner Cui Xiangmin — 10% owner | Conversion (C): 2,333,887 · Conversion (C): 333,412 · Purchase (P): 625,000 @ $16 · Purchase (P): 625,000 @ $16 · Conversion (C): 19,777,363 (derivative) @ $0 · Conversion (C): 2,825,337 (derivative) @ $0 | EDGAR |
Recent 8-K events — Aardvark Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-17 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-23 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-27 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AARD returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →